National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

NCPE Assessment Process Complete
Rapid review received 10/09/2018
Rapid review completed 18/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.

 

Full pharmacoeconomic assessment commissioned by HSE 22/10/2018
Pre-submission consultation with Applicant 03/12/2018
Submission received from applicant 20/03/2019
Current Status HTA submission received